

# Ann K Daly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899205/publications.pdf>

Version: 2024-02-01

280  
papers

28,911  
citations

4370

86  
h-index

5806

161  
g-index

324  
all docs

324  
docs citations

324  
times ranked

20108  
citing authors

#	ARTICLE	IF	CITATIONS
1	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	1.8	33
2	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
3	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	1.8	54
4	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31
5	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
6	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprimâ€Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021, 73, 268-281.	3.6	43
7	PharmVar GeneFocus: <i>CYP2C19</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 352-366.	2.3	72
8	Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	2.3	31
9	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021, 74, 20-30.	1.8	77
10	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	3.6	54
11	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
12	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021, 13, 1412.	1.7	26
13	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4546-4548.	1.1	4
14	PharmVar GeneFocus: <i>CYP2C9</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 662-676.	2.3	34
15	Transcriptomics Identify Thrombospondinâ€2 as a Biomarker for NASH and Advanced Liver Fibrosis. <i>Hepatology</i> , 2021, 74, 2452-2466.	3.6	71
16	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
17	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021, 116, 106-115.	0.2	25
18	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	5.8	17
20	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. <i>DNA and Cell Biology</i> , 2020, 39, 349-354.	0.9	10
21	Pharmacogenomics of Drug-Induced Liver Injury. <i>Advances in Molecular Pathology</i> , 2020, 3, 107-115.	0.2	3
22	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
23	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. <i>Toxicological Sciences</i> , 2020, 178, 115-126.	1.4	14
24	Polygenic architecture informs potential vulnerability to drug-induced liver injury. <i>Nature Medicine</i> , 2020, 26, 1541-1548.	15.2	55
25	HLA associations with infliximab-induced liver injury. <i>Pharmacogenomics Journal</i> , 2020, 20, 681-686.	0.9	17
26	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, 252-262.	1.8	170
27	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
28	Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury. <i>Hepatology Communications</i> , 2019, 3, 1032-1035.	2.0	7
29	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
30	Endocytosis and Lack of Cytotoxicity of Alkyl-Capped Silicon Quantum Dots Prepared from Porous Silicon. <i>Materials</i> , 2019, 12, 1702.	1.3	7
31	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	2.3	52
32	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134.	1.1	10
33	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	0.6	97
34	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. <i>Toxicology Research</i> , 2018, 7, 347-357.	0.9	70
35	Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI). <i>Methods in Pharmacology and Toxicology</i> , 2018, , 497-509.	0.1	1
36	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. <i>Alcohol</i> , 2018, 66, 1-7.	0.8	13

#	ARTICLE	IF	CITATIONS
37	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 178-187.	2.3	14
38	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. <i>Chemical Research in Toxicology</i> , 2018, 31, 1022-1024.	1.7	9
39	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. <i>Journal of Personalized Medicine</i> , 2018, 8, 1.	1.1	136
40	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Pharmacology</i> , 2018, 83, 155-190.	1.2	32
41	Genetic risk factors for DILI-recent findings from large international networks. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY76-2.	0.0	0
42	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 465-472.	1.9	8
43	Drug-Induced Cholestasis: Mechanisms and Importance. , 2017, , 117-128.		0
44	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , 2017, 67, 137-144.	1.8	100
45	Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?. <i>Pharmaceutical Research</i> , 2017, 34, 1564-1569.	1.7	33
46	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
47	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 454-464.	1.9	4
48	Pharmacogenetics: a general review on progress to date. <i>British Medical Bulletin</i> , 2017, 124, 1-15.	2.7	48
49	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	1.3	43
50	Defining drug response for stratified medicine. <i>Drug Discovery Today</i> , 2017, 22, 173-179.	3.2	24
51	HLA-DRB1*16. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 218-224.	0.7	63
52	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 172-185.	2.3	146
53	The Effect of the <i>CYP1A1*2A</i> Allele on Colorectal Cancer Susceptibility in a British Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 475-477.	0.3	3
54	Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 762-768.e1.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 158-165.	4.3	135
56	A multi-factorial analysis of response to warfarin in a UK prospective cohort. <i>Genome Medicine</i> , 2016, 8, 2.	3.6	41
57	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016, 9, 26-40.	1.4	11
58	Genetics of Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 361-374.	1.8	39
59	Brief Report: Genetics of Alcoholic Cirrhosisâ€” <sc>G</sc>enom<sc>ALC</sc> Multinational Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 836-842.	1.4	29
60	Characterization of amoxicillinâ€”and clavulanic acidâ€”specific T cells in patients with amoxicillinâ€”clavulanateâ€”induced liver injury. <i>Hepatology</i> , 2015, 62, 887-899.	3.6	83
61	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	0.8	28
62	PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 846-856.	0.2	120
63	TM6SF2 as a genetic risk factor for fibrosis. <i>Hepatology</i> , 2015, 62, 1321-1321.	3.6	3
64	Oral anticoagulation: a critique of recent advances and controversies. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 153-163.	4.0	70
65	Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 165-174.	0.3	18
66	Promiscuous T-cell responses to drugs and drug-haptens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 474-476.e8.	1.5	41
67	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015, 136, 94-100.	0.8	2
68	TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?. <i>Gastroenterology</i> , 2015, 148, 679-684.	0.6	75
69	Polymorphic Variants of Cytochrome P450. <i>Advances in Pharmacology</i> , 2015, 74, 85-111.	1.2	34
70	Pharmacogenomics of Warfarin. , 2014, , 497-507.		0
71	Direct-to-consumer pharmacogenomic testing assessed in a US-based study. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2014, 44, 212-213.	0.2	0
72	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <i>Cell Cycle</i> , 2014, 13, 1489-1494.	1.3	54

#	ARTICLE	IF	CITATIONS
73	Genetic Basis of Drug-Induced Liver Injury: Present and Future. <i>Seminars in Liver Disease</i> , 2014, 34, 123-133.	1.8	101
74	Pharmacogeneticâ€guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 626-641.	1.1	113
75	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 15-17.	2.3	15
76	Is There a Need to Teach Pharmacogenetics?. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 245-247.	2.3	17
77	Identification of susceptible HLA class II coâ€amoxiclav genotypes based on the analysis of drugâ€specific Tâ€cells from patients with liver injury. <i>Clinical and Translational Allergy</i> , 2014, 4, O3.	1.4	2
78	Characterization of amoxicillin and clavulanicâ€acidâ€responsive CD4+ And CD8+ Tâ€cells in patients with coâ€amoxiclavâ€induced liver injury. <i>Clinical and Translational Allergy</i> , 2014, 4, P42.	1.4	0
79	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1079-1086.	0.8	56
80	Opportunities and limitations: the value of pharmacogenetics in clinical practice. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 583-586.	1.1	7
81	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	5.8	478
82	Carriage of the PNPLA3 rs738409 C &gt;G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 75-81.	1.8	431
83	Point of care testing for improving risk- benefit ratio of aspirin and warfarin. <i>Molecular Cytogenetics</i> , 2014, 7, I54.	0.4	0
84	Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls. <i>Current Drug Metabolism</i> , 2014, 15, 196-201.	0.7	20
85	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. <i>Archives of Toxicology</i> , 2013, 87, 407-420.	1.9	50
86	Relevance of CYP2E1 to Non-alcoholic Fatty Liver Disease. <i>Sub-Cellular Biochemistry</i> , 2013, 67, 165-175.	1.0	17
87	A Randomized Trial of Genotype-Guided Dosing of Warfarin. <i>New England Journal of Medicine</i> , 2013, 369, 2294-2303.	13.9	735
88	Pharmacogenomics of adverse drug reactions. <i>Genome Medicine</i> , 2013, 5, 5.	3.6	87
89	Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. <i>Journal of Clinical Virology</i> , 2013, 58, 331-333.	1.6	17
90	Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury. , 2013, , 215-225.		0

#	ARTICLE	IF	CITATIONS
91	Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. <i>Clinica Chimica Acta</i> , 2013, 416, 11-19.	0.5	58
92	Adaptive Dosing Approaches to the Individualization of 13- <i>Cis</i> -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 469-479.	3.2	45
93	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <i>Hepatology</i> , 2013, 57, 727-739.	3.6	212
94	Institutional Profile: Pharmacogenomics research at Newcastle University. <i>Pharmacogenomics</i> , 2012, 13, 1333-1338.	0.6	0
95	CYP2D6 update. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 692-694.	0.7	19
96	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 784-795.	0.7	108
97	Genetic Polymorphisms Affecting Drug Metabolism. <i>Advances in Pharmacology</i> , 2012, 63, 137-167.	1.2	35
98	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	0.6	17
99	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. <i>Journal of Hepatology</i> , 2012, 56, 448-454.	1.8	156
100	Genetic association studies in drug-induced liver injury. <i>Drug Metabolism Reviews</i> , 2012, 44, 116-126.	1.5	100
101	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. <i>Blood</i> , 2012, 119, 868-873.	0.6	99
102	Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 21-35.	4.2	100
103	The population pharmacokinetics of <i>R</i> - and <i>S</i> -warfarin: effect of genetic and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 66-76.	1.1	70
104	Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 606-614.	1.9	22
105	An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 767-772.	1.9	15
106	Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity. <i>Gastroenterology</i> , 2011, 140, 1694-1695.	0.6	14
107	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
108	A Genome-Wide Association Study Identifies Potential Susceptibility Loci for Hepatotoxicity Due to Various Drugs. <i>Gastroenterology</i> , 2011, 140, S-886.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Genotypes and phenotypes of CYP3A in Bangladeshi population. <i>Clinica Chimica Acta</i> , 2011, 412, 531-536.	0.5	9
110	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. <i>Clinica Chimica Acta</i> , 2011, 412, 2063-2069.	0.5	33
111	Genetic modifiers of non-alcoholic fatty liver disease progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1557-1566.	1.8	59
112	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. <i>Journal of Hepatology</i> , 2011, 55, 1409-1414.	1.8	74
113	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 253-263.	1.4	53
114	Family History of Cancer and Tobacco Exposure in Index Cases of Pancreatic Ductal Adenocarcinoma. <i>Journal of Oncology</i> , 2011, 2011, 1-7.	0.6	11
115	Cyclooxygenase-2 Polymorphisms and Pancreatic Cancer Susceptibility. <i>Pancreas</i> , 2011, 40, 1289-1294.	0.5	11
116	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. <i>British Journal of Pharmacology</i> , 2011, 162, 989-999.	2.7	14
117	The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 784-785.	2.3	61
118	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 806-815.	2.3	773
119	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. <i>European Heart Journal</i> , 2011, 32, 1909-1917.	1.0	86
120	Genetics of Alcoholic and Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2011, 31, 128-146.	1.8	101
121	A common polymorphism in the <i>ABCB11</i> gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2011, 120, 287-296.	1.8	44
122	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1981-1986.	0.3	84
123	Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. <i>British Journal of Nutrition</i> , 2010, 103, 1585-1593.	1.2	40
124	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	0.6	26
125	A role for the pregnane X receptor in flucloxacillin-induced liver injury. <i>Hepatology</i> , 2010, 51, 1656-1664.	3.6	55
126	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. <i>Hepatology</i> , 2010, 51, 1463-1465.	3.6	26



#	ARTICLE	IF	CITATIONS
127	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 1209-1217.	3.6	563
128	Reversal of warfarin-induced over-anticoagulation with individualised dosing of oral vitamin k: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1123-5.	1.9	6
129	Preempting and preventing drug-induced liver injury. <i>Nature Genetics</i> , 2010, 42, 650-651.	9.4	25
130	Genome-wide association studies in pharmacogenomics. <i>Nature Reviews Genetics</i> , 2010, 11, 241-246.	7.7	238
131	Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1211-1217.	1.7	15
132	Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1261-1266.	1.7	21
133	Polymorphisms in the Tropomyosin TPM1 Short Isoform Promoter Alter Gene Expression and Are Associated With Increased Risk of Metabolic Syndrome. <i>American Journal of Hypertension</i> , 2010, 23, 399-404.	1.0	5
134	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010, 59, 267-273.	6.1	148
135	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF $\kappa$ B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1315-1320.	0.5	74
136	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. <i>Journal of Hepatology</i> , 2010, 53, 1049-1053.	1.8	137
137	Pharmacogenetics and human genetic polymorphisms. <i>Biochemical Journal</i> , 2010, 429, 435-449.	1.7	91
138	Drug-induced liver injury: past, present and future. <i>Pharmacogenomics</i> , 2010, 11, 607-611.	0.6	69
139	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009, 10, 1687-1695.	0.6	131
140	Genetic Association Studies in Drug-Induced Liver Injury. <i>Seminars in Liver Disease</i> , 2009, 29, 400-411.	1.8	98
141	Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype. <i>British Journal of Nutrition</i> , 2009, 101, 1316.	1.2	40
142	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , 2009, 41, 816-819.	9.4	950
143	Pharmacogenomics of anticoagulants: steps toward personal dosage. <i>Genome Medicine</i> , 2009, 1, 10.	3.6	33
144	Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. <i>New England Journal of Medicine</i> , 2009, 360, 753-764.	13.9	1,375

#	ARTICLE	IF	CITATIONS
145	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 565-566.	0.7	30
146	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 800-812.	0.7	57
147	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. <i>Toxicology</i> , 2008, 253, 10.	2.0	8
148	Relevance of PXR to Flucloxacillin-induced Liver Injury. <i>Toxicology</i> , 2008, 253, 2.	2.0	0
149	Flucloxacillin-induced liver injury. <i>Toxicology</i> , 2008, 254, 158-163.	2.0	29
150	Pharmacogenomics Applications in Drug Metabolism. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 109-120.	0.1	0
151	The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver. <i>Drug Metabolism and Disposition</i> , 2007, 35, 315-320.	1.7	20
152	Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes. <i>Gastroenterology</i> , 2007, 132, 272-281.	0.6	318
153	Genetic susceptibility in pancreatic ductal adenocarcinoma. <i>British Journal of Surgery</i> , 2007, 95, 22-32.	0.1	19
154	Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 555-565.	2.3	32
155	Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. <i>Genes and Nutrition</i> , 2007, 2, 225-232.	1.2	83
156	Individualized drug therapy. <i>Current Opinion in Drug Discovery &amp; Development</i> , 2007, 10, 29-36.	1.9	9
157	Genotyping for Cytochrome P450 Polymorphisms. , 2006, 320, 193-208.		23
158	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 3-15.	1.5	13
159	Significance of the Minor Cytochrome P450 3A Isoforms. <i>Clinical Pharmacokinetics</i> , 2006, 45, 13-31.	1.6	205
160	APOE genotype makes a small contribution to warfarin dose requirements. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 609-611.	0.7	46
161	A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1158-1159.	1.9	9
162	The impact of simvastatin on warfarin disposition and dose requirements. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1422-1424.	1.9	21

#	ARTICLE	IF	CITATIONS
163	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 468-478.	2.3	320
164	Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. <i>Cell Biochemistry and Function</i> , 2005, 23, 73-76.	1.4	35
165	Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. <i>Gut</i> , 2005, 54, 1579-1584.	6.1	35
166	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. <i>Blood</i> , 2005, 106, 2329-2333.	0.6	894
167	Pharmacogenetics of oral anticoagulants. <i>Personalized Medicine</i> , 2005, 2, 23-27.	0.8	3
168	Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. <i>Postgraduate Medical Journal</i> , 2004, 80, 107-109.	0.9	33
169	N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population. <i>International Journal of Toxicology</i> , 2004, 23, 25-31.	0.6	18
170	CYP3A5 phenotype-genotype correlations in a British population. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 664-664.	1.1	0
171	Development of analytical technology in pharmacogenetic research. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 133-140.	1.4	17
172	Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. <i>Hepatology</i> , 2004, 39, 1430-1440.	3.6	216
173	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004, 110, 266-270.	2.3	21
174	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 204-212.	2.3	183
175	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	2.3	171
176	Upstream and coding region CYP2C9 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 813-822.	5.7	87
177	Pharmacogenetics of the Cytochromes P450. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1733-1744.	1.0	112
178	Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. <i>Hepatology</i> , 2003, 37, 410-419.	3.6	61
179	Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. <i>Archives of Toxicology</i> , 2003, 77, 313-320.	1.9	39
180	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 380-387.	2.3	154

#	ARTICLE	IF	CITATIONS
181	Pharmacogenetics of the major polymorphic metabolizing enzymes. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 27-41.	1.0	167
182	CYP3A5 phenotype-genotype correlations in a British population. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 625-629.	1.1	65
183	Candidate gene case-control studies. <i>Pharmacogenomics</i> , 2003, 4, 127-139.	0.6	27
184	Altered Tropomyosin Expression in Essential Hypertension. <i>Hypertension</i> , 2003, 41, 347-354.	1.3	17
185	Genetic Regulation of Warfarin Metabolism and Response. <i>Seminars in Vascular Medicine</i> , 2003, 03, 231-238.	2.1	24
186	Pharmacogenetics of oral anticoagulants. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 247-252.	5.7	177
187	Warfarin sensitivity: be aware of genetic influence. <i>Age and Ageing</i> , 2003, 32, 226-227.	0.7	9
188	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients <sup>1 2</sup> . <i>Transplantation</i> , 2003, 76, 1233-1235.	0.5	257
189	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. <i>Carcinogenesis</i> , 2002, 23, 1343-1350.	1.3	250
190	Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A HuGE Review. <i>American Journal of Epidemiology</i> , 2002, 156, 95-109.	1.6	209
191	Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 121-132.	5.7	295
192	Polymorphisms in Immunoregulatory Genes. <i>Molecular Diagnosis and Therapy</i> , 2002, 2, 13-23.	3.3	19
193	CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6 $\beta$ -hydroxylase activity in human liver microsomes. <i>Biochemical Pharmacology</i> , 2002, 64, 1579-1589.	2.0	224
194	Pharmacogenetics of Tardive Dyskinesia Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism. <i>Neuropsychopharmacology</i> , 2002, 27, 105-119.	2.8	217
195	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. <i>Hepatology</i> , 2002, 36, 1355-1360.	3.6	50
196	Cytochrome P450 CYP1B1 and catechol O -methyltransferase ( COMT ) genetic polymorphisms and breast cancer susceptibility in a Turkish population. <i>Archives of Toxicology</i> , 2002, 76, 643-649.	1.9	76
197	CYP2C9 polymorphism and warfarin dose requirements. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 408-409.	1.1	24
198	CYP2D6 deficiency, a factor in ecstasy related deaths?. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 69-70.	1.1	33

#	ARTICLE	IF	CITATIONS
199	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. <i>Hepatology</i> , 2002, 36, 1355-1360.	3.6	23
200	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 555-572.	5.7	293
201	Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 45-55.	5.7	101
202	Candidate gene case-control association studies: advantages and potential pitfalls. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 489-499.	1.1	141
203	Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. <i>International Journal of Cancer</i> , 2001, 92, 777-783.	2.3	88
204	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1520-1525.	1.1	41
205	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. <i>Nature Genetics</i> , 2001, 27, 383-391.	9.4	1,954
206	Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. <i>Genes and Immunity</i> , 2001, 2, 44-47.	2.2	46
207	Pharmacogenetics of cytotoxic drugs. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 301-308.	1.1	1
208	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 511-518.	5.7	105
209	Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 11-24.	5.7	137
210	Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 91-93.	5.7	66
211	The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 240-243.	1.1	11
212	CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 77-80.	1.1	28
213	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. <i>Biochemical Pharmacology</i> , 2000, 60, 517-526.	2.0	150
214	Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 61-65.	1.0	40
215	Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. <i>Gut</i> , 2000, 46, 540-545.	6.1	156
216	Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. <i>Human Molecular Genetics</i> , 2000, 9, 1563-1566.	1.4	79

#	ARTICLE	IF	CITATIONS
217	Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. <i>Lung Cancer</i> , 2000, 28, 147-155.	0.9	70
218	CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000, 32, 538-541.	1.8	169
219	Warfarin dose requirement and CYP2C9 polymorphisms. <i>Lancet, The</i> , 1999, 353, 1972-1973.	6.3	20
220	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. <i>Lancet, The</i> , 1999, 353, 717-719.	6.3	1,181
221	Genetic variation of CYP2A6, smoking, and risk of cancer. <i>Lancet, The</i> , 1999, 353, 898-899.	6.3	137
222	Tumour necrosis factor- $\alpha$ promoter polymorphisms in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1999, 30, 232-236.	1.8	79
223	GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES. <i>Drug Metabolism Reviews</i> , 1999, 31, 467-487.	1.5	92
224	Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 327-332.	5.7	46
225	Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 367-376.	5.7	50
226	CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 31-36.	5.7	48
227	Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. <i>Hepatology</i> , 1998, 27, 1695-1699.	3.6	205
228	Tumour necrosis factor- $\alpha$ gene promoter polymorphism and decreased insulin resistance. <i>Diabetologia</i> , 1998, 41, 430-434.	2.9	111
229	No evidence for involvement of the interleukin-10 $\hat{\nu}$ 592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1998, 28, 820-823.	1.8	34
230	Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. <i>Toxicology Letters</i> , 1998, 102-103, 143-147.	0.4	53
231	Heterozygotes for <i>HFE</i> mutations have no increased risk of advanced alcoholic liver disease. <i>Gut</i> , 1998, 43, 262-266.	6.1	86
232	Analysis of Cytochrome P450 Polymorphisms. , 1998, 107, 405-422.		15
233	The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 335-342.	5.7	94
234	An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 129-136.	5.7	95

#	ARTICLE	IF	CITATIONS
235	CYP2D6 phenotype ??? genotype relationships in African-Americans and Caucasians in Los Angeles. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 529-542.	5.7	111
236	Detection and characterization of novel polymorphisms in the CYP2E1 gene. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 543-552.	5.7	99
237	Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. <i>Carcinogenesis</i> , 1997, 18, 1351-1354.	1.3	109
238	CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1207-1212.	3.0	178
239	Genetic polymorphism of CYP2D6 and lung cancer risk in African- Americans and Caucasians in Los Angeles County. <i>Carcinogenesis</i> , 1997, 18, 1203-1214.	1.3	66
240	Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 149-152.	5.7	15
241	Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 401-404.	5.7	37
242	Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. <i>British Journal of Psychiatry</i> , 1997, 170, 23-26.	1.7	94
243	Presenilin polymorphisms in Alzheimer's disease. <i>Lancet, The</i> , 1997, 350, 958-959.	6.3	12
244	Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. <i>Hepatology</i> , 1997, 26, 143-146.	3.6	315
245	Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. <i>FEBS Letters</i> , 1996, 392, 30-34.	1.3	181
246	[22] CYP2D6 multiallelism. <i>Methods in Enzymology</i> , 1996, 272, 199-210.	0.4	117
247	Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 527-533.	5.7	77
248	Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 151-158.	5.7	48
249	Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype??. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 319-328.	5.7	53
250	Nomenclature for human CYP2D6 alleles. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 193-201.	5.7	403
251	Stereoselective cardiotoxic effects of terodiline. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 89-98.	2.3	41
252	Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 66-68.	0.5	53



#	ARTICLE	IF	CITATIONS
253	Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 215-223.	5.7	248
254	Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 234-243.	5.7	35
255	Molecular basis of polymorphic drug metabolism. <i>Journal of Molecular Medicine</i> , 1995, 73, 539-53.	1.7	97
256	An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. <i>Human Genetics</i> , 1995, 95, 337-41.	1.8	36
257	Polymorphism of Glutathione S-Transferase M1 and Lung Cancer Risk Among African-Americans and Caucasians in Los Angeles County, California. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1246-1253.	3.0	126
258	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. <i>Biochemical Pharmacology</i> , 1994, 47, 1157-1163.	2.0	113
259	Poor metabolisers of nicotine and CYP2D6 polymorphism. <i>Lancet, The</i> , 1994, 343, 62-63.	6.3	64
260	Genotyping of the CYP 2D6 gene in Norwegian lung cancer patients and controls. <i>Pharmacogenetics and Genomics</i> , 1994, 4, 47-57.	5.7	26
261	Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. <i>Pharmacogenetics and Genomics</i> , 1994, 4, 159-161.	5.7	11
262	The cytochrome P450 CYP2D6 allelic variant CYP 2D6J and related polymorphisms in a European population. <i>Pharmacogenetics and Genomics</i> , 1994, 4, 73-81.	5.7	55
263	A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. <i>Human Genetics</i> , 1993, 91, 616-7.	1.8	19
264	Metabolic polymorphisms. , 1993, 57, 129-160.		172
265	New Opportunities in Cancer Risk Evaluation Using PCR-Based DNA Analysis for CYP2D6. <i>Environmental Health Perspectives</i> , 1993, 101, 117.	2.8	1
266	Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. <i>Pharmacogenetics and Genomics</i> , 1992, 2, 19-24.	5.7	16
267	The pharmacogenetics of chemical carcinogenesis. <i>Pharmacogenetics and Genomics</i> , 1992, 2, 246-258.	5.7	59
268	Mutant debrisoquine hydroxylation genes in Parkinson's disease. <i>Lancet, The</i> , 1992, 339, 1017-1018.	6.3	248
269	The role of individual human cytochromes P450 in drug metabolism and clinical response. <i>Trends in Pharmacological Sciences</i> , 1992, 13, 434-439.	4.0	229
270	Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 6.	5.7	106



#	ARTICLE	IF	CITATIONS
271	[24] Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalian cells. <i>Methods in Enzymology</i> , 1990, 189, 239-247.	0.4	12
272	[31] Cellular retinoic acid-binding protein from neonatal rat skin: Purification and analysis. <i>Methods in Enzymology</i> , 1990, 189, 307-314.	0.4	0
273	Molecular genotyping to predict debrisoquine hydroxylation phenotype. <i>Lancet, The</i> , 1990, 336, 889-890.	6.3	6
274	The biological activity of retinoids in melanoma cells. <i>FEBS Letters</i> , 1990, 273, 19-22.	1.3	25
275	Nuclear Retinoic-Acid-Binding Proteins and Receptors in Retinoic-Acid-Responsive Cell Lines. <i>Pathobiology</i> , 1989, 57, 339-345.	1.9	1
276	Purification and properties of cellular retinoic acid-binding protein from neonatal rat skin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1988, 965, 118-126.	1.1	14
277	Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei. <i>FEBS Journal</i> , 1987, 168, 133-139.	0.2	37
278	Kinetic Studies on the Major form of Aldehyde Reductase in ox Kidney: a General Kinetic Mechanism to Explain Substrate-Dependent Mechanisms and the Inhibition by Anticonvulsants. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1986, 1, 163-168.	0.5	7
279	Interphase nuclear matrix and metaphase scaffolding structures. <i>Journal of Cell Science</i> , 1984, 1984, 103-122.	1.2	87
280	The kinetic mechanism of the major form of ox kidney aldehyde reductase with <sc>d</sc>-glucuronic acid. <i>Biochemical Journal</i> , 1982, 205, 381-388.	1.7	15